Wedbush analyst Laura Chico lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $33 and keeps an Outperform rating on the shares. Overall, the Q4 financial results update from the company was largely uneventful, the firm says. Most notable in the update, all key pipeline development timelines remain on track, including the tividenofusp alfa BLA submission, Wedbush adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Positive Outlook for Denali Therapeutics: Strategic Progress and Promising Developments Support Buy Rating
- Denali Therapeutics: Promising ETV Platform and Strategic Advancements Justify Buy Rating
- Denali Therapeutics price target lowered to $80 from $87 at H.C. Wainwright
- Denali Therapeutics Reports 2024 Financial Results and Progress
- Denali Therapeutics Signs New Equity Distribution Deal
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue